[go: up one dir, main page]

MA44922A1 - Anticorps - Google Patents

Anticorps

Info

Publication number
MA44922A1
MA44922A1 MA44922A MA44922A MA44922A1 MA 44922 A1 MA44922 A1 MA 44922A1 MA 44922 A MA44922 A MA 44922A MA 44922 A MA44922 A MA 44922A MA 44922 A1 MA44922 A1 MA 44922A1
Authority
MA
Morocco
Prior art keywords
antibody
binding
fragment
present
dna
Prior art date
Application number
MA44922A
Other languages
English (en)
Other versions
MA44922B1 (fr
Inventor
Graham Craggs
Karine Jeannine Madeleine Herve
Diane Marshall
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44922(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA44922A1 publication Critical patent/MA44922A1/fr
Publication of MA44922B1 publication Critical patent/MA44922B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne un anticorps anti-csf-1r et des fragments de liaison associés, de l'adn codant pour celui-ci, des cellules hôtes comportant ledit adn et des méthodes d'expression de l'anticorps ou d'un fragment de liaison dans une cellule hôte. La présente invention s'étend également à des compositions pharmaceutiques comprenant l'anticorps ou un fragment de liaison associé, et l'utilisation de l'anticorps, du fragment de liaison et des compositions les comprenant dans un traitement.
MA44922A 2013-08-30 2014-08-26 Anticorps MA44922B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315487.7A GB201315487D0 (en) 2013-08-30 2013-08-30 Antibodies
PCT/EP2014/068050 WO2015028455A1 (fr) 2013-08-30 2014-08-26 Anticorps

Publications (2)

Publication Number Publication Date
MA44922A1 true MA44922A1 (fr) 2019-08-30
MA44922B1 MA44922B1 (fr) 2020-06-30

Family

ID=49397073

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38930A MA38930A1 (fr) 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)
MA44922A MA44922B1 (fr) 2013-08-30 2014-08-26 Anticorps

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38930A MA38930A1 (fr) 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)

Country Status (40)

Country Link
US (2) US9908939B2 (fr)
EP (3) EP3038643B1 (fr)
JP (3) JP6632075B2 (fr)
KR (1) KR102303130B1 (fr)
CN (2) CN112321711B (fr)
AR (1) AR097464A1 (fr)
AU (1) AU2014314304B2 (fr)
BR (1) BR112016004324B1 (fr)
CA (1) CA2922240C (fr)
CL (1) CL2016000438A1 (fr)
CY (1) CY1121964T1 (fr)
DK (2) DK3549599T5 (fr)
EA (1) EA036255B1 (fr)
ES (2) ES2965207T3 (fr)
FI (1) FI3549599T3 (fr)
GB (1) GB201315487D0 (fr)
HK (1) HK1220142A1 (fr)
HR (2) HRP20231264T1 (fr)
HU (2) HUE064437T2 (fr)
IL (1) IL244043B (fr)
LT (2) LT3038643T (fr)
MA (2) MA38930A1 (fr)
MX (1) MX372950B (fr)
MY (1) MY172484A (fr)
NZ (1) NZ717399A (fr)
PE (2) PE20201067A1 (fr)
PH (1) PH12016500275B1 (fr)
PL (2) PL3038643T3 (fr)
PT (2) PT3038643T (fr)
RS (2) RS59019B1 (fr)
SG (1) SG11201601151PA (fr)
SI (2) SI3038643T1 (fr)
SM (2) SMT202300409T1 (fr)
TN (1) TN2016000067A1 (fr)
TR (1) TR201909478T4 (fr)
TW (1) TWI531582B (fr)
UA (1) UA118354C2 (fr)
UY (1) UY35718A (fr)
WO (1) WO2015028455A1 (fr)
ZA (1) ZA201601437B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
CN107660152B (zh) * 2015-05-27 2021-11-05 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
WO2016196679A1 (fr) * 2015-06-02 2016-12-08 Genentech, Inc. Compositions et méthodes d'utilisation d'anticorps anti-il -34 pour traiter des maladies neurologiques
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
WO2018119142A1 (fr) 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
WO2018183366A1 (fr) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Polythérapies d'anticorps csf-1r ou csf-1 et thérapie reposant sur des lymphocytes t
EP3624848A1 (fr) * 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Polythérapies
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
CN108948198B (zh) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其应用
EP3894014A4 (fr) * 2018-12-13 2022-04-20 Development Center for Biotechnology Anticorps anti-csf-1r humain et ses utilisations
CN113939539B (zh) * 2019-05-15 2024-06-04 博奥信生物技术（南京）有限公司 结合csf-1r的抗体及其用途
IL293705A (en) * 2019-12-09 2022-08-01 Syndax Pharmaceuticals Inc Antibodies for the treatment of chronic graft versus host disease
EP4081255A4 (fr) * 2019-12-24 2024-04-03 Adagene (Suzhou) Limited Molécules anti-csf1r et utilisation correspondante
TW202446418A (zh) 2023-05-17 2024-12-01 美商錫達斯醫藥股份有限公司 使用抗群落刺激因子１受體抗體治療慢性移植物抗宿主病相關閉塞性細支氣管炎症候群之方法
US20250051432A1 (en) 2023-07-23 2025-02-13 Incyte Corporation Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EA201591355A1 (ru) 2007-08-21 2016-04-29 Амген Инк. АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
CA2700714C (fr) 2007-09-26 2018-09-11 Ucb Pharma S.A. Fusions d'anticorps a double specificite
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
MX2010009894A (es) 2008-03-14 2011-02-22 Transgene Sa Anticuerpo contra csf-1r.
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI0918947A2 (pt) 2008-09-26 2015-12-01 Ucb Pharma Sa proteína de fusão de anticorpo
EP2475682B1 (fr) 2009-09-10 2018-01-31 UCB Biopharma SPRL Anticorps multivalents
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
SI2949670T1 (sl) 2009-12-10 2019-05-31 F. Hoffmann-La Roche Ag Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US9221910B2 (en) * 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
BR112012020372A8 (pt) * 2010-03-05 2018-01-02 Hoffmann La Roche anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
RS58211B1 (sr) * 2010-05-04 2019-03-29 Five Prime Therapeutics Inc Antitela koja vezuju csf1r
KR20140113683A (ko) * 2011-12-15 2014-09-24 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
DK3549599T3 (en) 2023-10-30
TW201512221A (zh) 2015-04-01
BR112016004324A2 (pt) 2017-10-24
SMT202300409T1 (it) 2024-01-10
US20160200821A1 (en) 2016-07-14
HRP20231264T1 (hr) 2024-02-02
EP3549599A1 (fr) 2019-10-09
HRP20191051T1 (hr) 2019-09-06
US9908939B2 (en) 2018-03-06
EA201690503A1 (ru) 2016-06-30
CA2922240C (fr) 2023-09-05
IL244043B (en) 2021-01-31
CN112321711A (zh) 2021-02-05
AU2014314304B2 (en) 2019-12-05
EP3549599B1 (fr) 2023-09-06
GB201315487D0 (en) 2013-10-16
RS59019B1 (sr) 2019-08-30
US20180162947A1 (en) 2018-06-14
SMT201900471T1 (it) 2019-09-09
RS64784B1 (sr) 2023-11-30
US10421814B2 (en) 2019-09-24
KR20160044018A (ko) 2016-04-22
MX2016002166A (es) 2016-06-23
PE20160528A1 (es) 2016-05-21
EA036255B1 (ru) 2020-10-20
WO2015028455A1 (fr) 2015-03-05
ES2733735T3 (es) 2019-12-02
LT3549599T (lt) 2023-11-10
JP2022002523A (ja) 2022-01-11
EP3038643B1 (fr) 2019-05-01
JP2016529266A (ja) 2016-09-23
MA44922B1 (fr) 2020-06-30
CL2016000438A1 (es) 2016-11-11
PH12016500275A1 (en) 2016-05-02
PH12016500275B1 (en) 2019-11-29
EP4282881A2 (fr) 2023-11-29
MY172484A (en) 2019-11-26
PE20201067A1 (es) 2020-10-19
TN2016000067A1 (en) 2017-07-05
MA38930A1 (fr) 2017-12-29
PL3549599T3 (pl) 2024-03-04
PT3549599T (pt) 2023-11-21
SI3549599T1 (sl) 2023-12-29
CY1121964T1 (el) 2020-10-14
NZ717399A (en) 2021-12-24
TWI531582B (zh) 2016-05-01
SI3038643T1 (sl) 2019-08-30
CN112321711B (zh) 2024-11-08
CN105658236B (zh) 2021-03-19
BR112016004324B1 (pt) 2024-01-16
HUE045672T2 (hu) 2020-01-28
UA118354C2 (uk) 2019-01-10
AU2014314304A1 (en) 2016-03-17
DK3549599T5 (da) 2024-09-02
KR102303130B1 (ko) 2021-09-16
JP7195237B2 (ja) 2022-12-23
PL3038643T3 (pl) 2019-11-29
AR097464A1 (es) 2016-03-16
HUE064437T2 (hu) 2024-03-28
JP6632075B2 (ja) 2020-01-15
CA2922240A1 (fr) 2015-03-05
FI3549599T3 (fi) 2023-10-31
HK1220142A1 (zh) 2017-04-28
DK3038643T3 (da) 2019-06-24
PT3038643T (pt) 2019-07-25
ZA201601437B (en) 2018-08-29
MX372950B (es) 2025-03-04
IL244043A0 (en) 2016-04-21
EP4282881A3 (fr) 2024-02-21
JP2020005652A (ja) 2020-01-16
CN105658236A (zh) 2016-06-08
ES2965207T3 (es) 2024-04-11
EP3038643A1 (fr) 2016-07-06
SG11201601151PA (en) 2016-03-30
UY35718A (es) 2015-03-27
LT3038643T (lt) 2019-07-25
TR201909478T4 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
MA44922A1 (fr) Anticorps
MA37619B1 (fr) Anticorps anti-fcrn
MA39096B1 (fr) Anticorps spécifiques à fcrn
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
EA201892774A1 (ru) Антитела
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
MA32948B1 (fr) Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
EA202092589A3 (ru) Cxcr2-связывающие полипептиды
MA38478A1 (fr) Anticorps anti-pac1 humains
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MA38400A1 (fr) Molécules fc bispécifiques
JO3623B1 (ar) البروتينات المرتبطة بمولد المستضاد st2
MA37407B1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MY199683A (en) Anti-pd-1 antibodies
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
EA201890941A1 (ru) Программируемые универсальные клеточные рецепторы и способы их применения
EA201591898A1 (ru) Антитела, направленные на m-csf
MX2016001193A (es) Medicamento que comprende anticuerpo anti-fosfolipasa d4.
MA39188A1 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci